238 related articles for article (PubMed ID: 28713268)
1. Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis
Wang C; Xiao F; Qu X; Zhai Z; Hu G; Chen X; Zhang X
Front Pharmacol; 2017; 8():407. PubMed ID: 28713268
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
3. Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption.
Niu C; Xiao F; Yuan K; Hu X; Lin W; Ma R; Zhang X; Huang Z
Front Pharmacol; 2017; 8():626. PubMed ID: 28955231
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of protein S-palmitoylation suppresses osteoclastogenesis and ameliorates ovariectomy-induced bone loss.
Ma L; Zhang L; Liao Z; Xiu C; Luo X; Luo N; Zhang L; He G; Chen J
J Orthop Translat; 2023 Sep; 42():1-14. PubMed ID: 37521493
[TBL] [Abstract][Full Text] [Related]
5. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
6. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
[TBL] [Abstract][Full Text] [Related]
7. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
[TBL] [Abstract][Full Text] [Related]
8. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
[TBL] [Abstract][Full Text] [Related]
9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
10. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
11. Pregnenolone Inhibits Osteoclast Differentiation and Protects Against Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss.
Sun X; Zhang C; Guo H; Chen J; Tao Y; Wang F; Lin X; Liu Q; Su L; Qin A
Front Pharmacol; 2020; 11():360. PubMed ID: 32292342
[TBL] [Abstract][Full Text] [Related]
12. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
[No Abstract] [Full Text] [Related]
13. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat.
Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS
J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458
[TBL] [Abstract][Full Text] [Related]
14. Ethanol extract of Polyscias fruticosa leaves suppresses RANKL-mediated osteoclastogenesis in vitro and LPS-induced bone loss in vivo.
Tran PT; Dang NH; Kim O; Van Cuong P; Dat NT; Hwangbo C; Van Minh C; Lee JH
Phytomedicine; 2019 Jun; 59():152908. PubMed ID: 30981187
[TBL] [Abstract][Full Text] [Related]
15. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
[TBL] [Abstract][Full Text] [Related]
16. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation.
Chen K; Yuan Y; Wang Z; Song D; Zhao J; Cao Z; Chen J; Guo Q; Chen L; Tickner J; Xu J
J Cell Physiol; 2019 May; 234(5):6477-6488. PubMed ID: 30341897
[TBL] [Abstract][Full Text] [Related]
17. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.
Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
Drug Des Devel Ther; 2015; 9():3755-66. PubMed ID: 26229438
[TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
19. Protocatechuic Acid Attenuates Osteoclastogenesis by Downregulating JNK/c-Fos/NFATc1 Signaling and Prevents Inflammatory Bone Loss in Mice.
Park SH; Kim JY; Cheon YH; Baek JM; Ahn SJ; Yoon KH; Lee MS; Oh J
Phytother Res; 2016 Apr; 30(4):604-12. PubMed ID: 26792397
[TBL] [Abstract][Full Text] [Related]
20. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
Hu B; Sun X; Yang Y; Ying Z; Meng J; Zhou C; Jiang G; Li S; Wu F; Zhao X; Zhu H; Wu H; Cai X; Shi Z; Yan S
FASEB J; 2019 Feb; 33(2):2574-2586. PubMed ID: 30285579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
